# Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

> **NCT00374660** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 63 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irofulven

## Key facts

- **NCT ID:** NCT00374660
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374660, "Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00374660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*